Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Zinc deficiency14.13.01.0010.000035%Not Available
Pneumoperitoneum07.07.01.0080.000297%Not Available
Tubulointerstitial nephritis20.05.02.0020.000105%Not Available
Fibromyalgia15.05.02.0020.000035%Not Available
Intracardiac thrombus02.11.01.017; 24.01.05.0030.000052%Not Available
Joint range of motion decreased15.01.02.0060.000052%
Dermatosis23.03.03.0170.000035%Not Available
Energy increased08.01.03.0170.000035%Not Available
Myofascial pain syndrome15.05.02.0030.000035%Not Available
Acute generalised exanthematous pustulosis12.03.01.005; 11.07.01.018; 10.01.01.034; 23.03.10.0020.000332%Not Available
Hypoacusis04.02.01.0060.000192%
Paradoxical drug reaction08.06.01.0140.000087%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000070%
Osteopenia15.02.03.003; 14.04.04.0040.000350%Not Available
Oesophagitis ulcerative07.04.05.003--Not Available
Onychomadesis23.02.05.0060.000087%
General physical health deterioration08.01.03.0180.000437%Not Available
Upper respiratory tract inflammation22.12.03.0340.000189%Not Available
Quadriparesis17.01.04.0120.000052%Not Available
Shock haemorrhagic24.06.02.014; 14.05.05.0030.000140%Not Available
Left ventricular hypertrophy02.04.02.0140.000035%Not Available
Muscle tightness15.05.03.0070.000070%Not Available
Pneumomediastinum22.09.03.0040.000140%Not Available
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.0120.000070%Not Available
Intervertebral disc protrusion15.10.01.0040.000070%Not Available
Subileus07.13.01.0040.000035%Not Available
Ventricular hypokinesia02.04.02.0130.000035%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.000035%Not Available
Deep vein thrombosis24.01.02.0030.000559%Not Available
Foreign body sensation in eyes06.01.01.0060.000035%Not Available
The 23th Page    First    Pre   23 24 25 26 27    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene